Hematopoietic Stem Cell TransplantationTransplantation, AutologousTransplantation ConditioningTransplantation, HomologousWhole-Body IrradiationLiver TransplantationGraft vs Host DiseaseDisease-Free SurvivalKidney TransplantationHematologic NeoplasmsBone Marrow TransplantationMyeloablative AgonistsImmunosuppressive AgentsStem Cell TransplantationGraft RejectionTreatment OutcomeRetrospective StudiesUnrelated DonorsHeart TransplantationPeripheral Blood Stem Cell TransplantationTransplantation ChimeraTissue DonorsHistocompatibility TestingHistocompatibilityCord Blood Stem Cell TransplantationGraft SurvivalTime FactorsVidarabineHematopoietic Stem CellsGraft vs Tumor EffectBusulfanRecurrenceSiblingsLeukemiaLeukemia, Myeloid, AcuteChimerismSurvival AnalysisHLA AntigensRemission InductionCell TransplantationGraft vs Leukemia EffectDonor SelectionProspective StudiesSurvival RateMyelodysplastic SyndromesTransplantation ImmunologyCombined Modality TherapyTransplantationHematologic DiseasesMultiple MyelomaDirected Tissue DonationHematopoiesisFollow-Up StudiesPrecursor Cell Lymphoblastic Leukemia-LymphomaSurvivorsMycophenolic AcidLymphoma, Non-HodgkinCyclosporineLung TransplantationAcute DiseaseCyclophosphamideImmunosuppressionLiving DonorsT-LymphocytesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLymphocyte TransfusionAntilymphocyte SerumBone Marrow CellsAllograftsMinor Histocompatibility AntigensAnemia, AplasticRisk FactorsMucopolysaccharidosis IHepatic Veno-Occlusive DiseaseAntigens, CD34Organ Transplantation